An ESR1 mutation test looks for acquired changes in the ESR1 gene, which encodes estrogen receptor alpha. In breast cancer, these mutations matter mainly in estrogen receptor-positive, HER2-negative advanced or metastatic disease because they can make the estrogen receptor active even when estrogen levels are suppressed. That can reduce the effectiveness of aromatase inhibitors and help explain why a cancer that was once hormone-sensitive has started to grow. ESR1 mutations are usually detected in tumor DNA or, increasingly, in circulating tumor DNA (ctDNA) from a blood sample. A positive result does not mean that all endocrine therapy has stopped working, and it does not by itself prove that a recurrence has occurred. Instead, it identifies a molecular resistance mechanism that can influence the choice and timing of endocrine treatment. The meaning of the result depends on the cancer stage, prior therapy, the specific mutation, and whether the test was performed on tissue or blood.
- A positive ESR1 mutation result usually indicates an acquired endocrine-resistance mechanism in ER-positive breast cancer, especially after aromatase inhibitor exposure.
- Blood-based ctDNA testing can detect ESR1 mutations without a new biopsy and may identify an emerging resistant clone before radiographic progression in selected patients.
- Common clinically relevant ESR1 mutations cluster in the ligand-binding domain, including D538G and Y537S/N/C.
- A negative blood test does not completely exclude an ESR1 mutation because some tumors shed little ctDNA; tissue testing may still be informative when clinically appropriate.
- An ESR1 mutation is not the same as estrogen-receptor loss, HER2 positivity, or hereditary breast-cancer risk.
Table of Contents
- What ESR1 Testing Measures
- When ESR1 Testing Is Used
- How the Test Is Performed
- How to Interpret ESR1 Mutation Results
- Treatment and Hormone-Resistance Meaning
- Recurrence Monitoring and Test Limitations
- Questions to Ask After ESR1 Testing
What ESR1 Testing Measures
The ESR1 gene provides instructions for estrogen receptor alpha, a protein that allows many breast cancer cells to use estrogen-related signaling for growth. In estrogen receptor-positive breast cancer, this receptor is one of the main biological drivers of the tumor and is also the target of endocrine treatments.
An ESR1 mutation test does not measure the amount of estrogen in the blood. It looks for changes in the DNA sequence of ESR1. The mutations that are most important in advanced breast cancer are usually somatic, meaning they developed in the cancer rather than being inherited in every cell of the body.
Most clinically important acquired ESR1 mutations occur in the receptor’s ligand-binding domain. Frequently reported examples include D538G, Y537S, Y537N, Y537C, E380Q, and L536 alterations. These changes can stabilize the estrogen receptor in an active state. As a result, the cancer cell may continue to receive growth signals even when an aromatase inhibitor has reduced estrogen production to very low levels.
That biological distinction is important. An ESR1 mutation is not the same as:
- a positive estrogen receptor immunohistochemistry result;
- a HER2 mutation, amplification, or protein-overexpression result;
- a germline BRCA1 or BRCA2 mutation;
- a general measure of tumor aggressiveness; or
- a blood tumor-marker level that rises and falls in a predictable numeric range.
There is therefore no “normal range” for an ESR1 mutation test. The result is usually reported as detected/positive, not detected/negative, or occasionally indeterminate/insufficient. When next-generation sequencing is used, the report may also provide the exact variant and a variant allele fraction, often abbreviated VAF.
Variant allele fraction describes the proportion of sequenced DNA molecules carrying the mutation in that sample. It can be useful context, but it is not a direct measure of tumor size. A low VAF can still be clinically meaningful if the alteration is well validated and the assay is sufficiently sensitive.
ESR1 testing also fits into broader molecular profiling. A patient with advanced ER-positive breast cancer may be tested for several actionable alterations, such as a PIK3CA mutation, because different findings can point toward different treatment strategies.
When ESR1 Testing Is Used
ESR1 testing is most useful in ER-positive, HER2-negative advanced or metastatic breast cancer that has been exposed to endocrine therapy, particularly an aromatase inhibitor. These mutations are uncommon in untreated primary breast cancer but become more frequent after treatment creates selective pressure on estrogen-dependent tumor cells.
In practical terms, testing may be considered when a patient has disease progression during or after endocrine treatment, when treatment selection depends on ESR1 status, or when a clinician is using serial ctDNA testing in a treatment strategy specifically validated for emerging ESR1 mutations.
The timing of testing matters because ESR1 status can change over the course of treatment. A tumor that was ESR1 wild type at the original diagnosis can later develop an ESR1-mutant subclone. For that reason, a molecular result from an old primary-tumor specimen may not reflect the biology of metastatic disease years later.
A major recent development is the use of serial blood-based ESR1 testing before scans show progression. In the SERENA-6 trial, patients receiving first-line aromatase inhibitor plus a CDK4/6 inhibitor underwent repeated ctDNA testing. When an ESR1 mutation emerged without radiographic progression, switching the aromatase inhibitor to camizestrant while continuing the CDK4/6 inhibitor prolonged progression-free survival. In September 2026, the U.S. Food and Drug Administration granted accelerated approval to camizestrant in that specific setting based on detection of an ESR1 mutation with an authorized test.
This does not mean that every patient with early-stage breast cancer should undergo serial ESR1 blood testing. The clinical evidence and treatment approvals apply to defined advanced-disease settings. Testing should be linked to a clear decision: what will change if the result is positive, and what will happen if it is negative?
ESR1 testing is also different from routine surveillance for recurrence after curative-intent treatment. A person with no known metastatic disease should not interpret an ESR1 result in isolation as proof of relapse. Standard follow-up still depends on symptoms, examination, imaging when indicated, pathology, and the overall clinical picture.
How the Test Is Performed
ESR1 mutations can be detected from plasma ctDNA or from tumor tissue. Both approaches have strengths and limitations.
Blood-based ctDNA testing
A liquid-biopsy assay analyzes small fragments of DNA released into the bloodstream by cancer cells. Blood collection is relatively easy, can be repeated, and can sample DNA from multiple tumor sites at once. This makes ctDNA especially attractive when metastatic lesions are difficult or risky to biopsy.
The laboratory typically separates plasma from blood cells, extracts cell-free DNA, and analyzes it with a validated next-generation sequencing or targeted molecular method. Some companion-diagnostic assays are specifically authorized to identify ESR1 mutations that qualify patients for particular therapies.
A key limitation is tumor shedding. Some cancers release abundant ctDNA; others release very little. Bone-predominant disease and small-volume disease can sometimes produce low ctDNA levels. If no ESR1 mutation is detected in plasma, the result may reflect a truly wild-type tumor, or the assay may simply not have received enough tumor-derived DNA to identify the alteration.
Tumor-tissue testing
Tissue testing uses DNA extracted from a biopsy or surgical specimen. A recent metastatic biopsy can provide valuable information about ESR1 and other tumor alterations while also confirming histology and receptor status.
The tradeoff is that a biopsy samples one location at one time. Metastatic breast cancer can be heterogeneous, meaning different tumor deposits may not have identical molecular profiles. Tissue availability, tumor percentage, fixation quality, and DNA quality can also affect whether testing succeeds.
Broad tumor profiling may include ESR1 as part of a cancer gene mutation panel. When clinicians need information about mutations, copy-number changes, and fusions together, a broader solid tumor NGS panel may be used instead of a single-gene test.
No special fasting is usually required for a blood-based ESR1 test. For tissue testing, the main issue is obtaining an adequate tumor specimen rather than patient preparation. Turnaround time varies by laboratory and platform and may range from several days to a few weeks.
How to Interpret ESR1 Mutation Results
A useful interpretation starts with three questions: Was a mutation detected? Is that mutation known to be activating or clinically relevant? Was the sample capable of detecting tumor DNA reliably?
| Result | What it usually means | What it does not mean |
|---|---|---|
| ESR1 mutation detected | An ESR1-mutant tumor clone is present; in the usual metastatic setting this often reflects acquired resistance to estrogen deprivation. | It does not mean all endocrine drugs are ineffective or that chemotherapy is automatically required. |
| ESR1 mutation not detected | No qualifying mutation was found in the tested sample at the assay’s detection limit. | It does not completely exclude an ESR1-mutant clone, especially when ctDNA levels are low. |
| Variant of uncertain significance | A change was found, but evidence may be insufficient to classify it as a resistance-driving alteration. | It should not automatically be treated like a validated activating ESR1 mutation. |
| Insufficient or indeterminate | The specimen or assay did not yield a dependable answer. | It is not the same as a negative result. |
The specific mutation can matter. D538G and Y537 substitutions are among the best characterized. Different ESR1 variants can alter receptor structure and drug sensitivity to different degrees, and multiple ESR1 mutations can coexist in the same patient after prolonged endocrine treatment.
A report may also show a mutation at a very low VAF. Low levels can represent a small resistant clone emerging under treatment pressure. In a validated serial-monitoring strategy, that early molecular signal may be actionable before the clone becomes dominant. Outside a validated clinical setting, however, one low-level result should be interpreted with the assay’s technical limits and the patient’s treatment history in mind.
Another common source of confusion is the phrase ESR1 positive. In pathology, “ER positive” usually refers to estrogen receptor protein detected by immunohistochemistry. “ESR1 mutation positive” means a DNA sequence alteration was detected. A tumor can be ER-positive by immunohistochemistry and have either mutant or wild-type ESR1.
Treatment and Hormone-Resistance Meaning
The main clinical value of ESR1 testing is that it can identify resistance to estrogen deprivation while preserving a potentially targetable dependence on the estrogen receptor itself. That is why an ESR1 mutation does not equal “endocrine therapy no longer works.” It more specifically means that certain endocrine approaches may work less well than others.
Aromatase inhibitors reduce estrogen production. Activating ESR1 mutations can allow the receptor to signal with less dependence on estrogen, so continuing the same aromatase-inhibitor strategy after an ESR1-driven resistance mechanism emerges may be less effective.
Other endocrine drugs interact more directly with the receptor. Selective estrogen receptor degraders and antagonists can retain activity in ESR1-mutant disease, although effectiveness differs by drug, clinical setting, prior treatment, and mutation biology.
As of September 2026, U.S. treatment options with ESR1-defined indications include elacestrant, imlunestrant, and vepdegestrant after prior endocrine therapy in appropriate ER-positive, HER2-negative advanced or metastatic disease. Vepdegestrant, approved in May 2026, is a heterobifunctional estrogen-receptor degrader and is another example of why the exact ESR1 result can directly affect drug eligibility. In addition, camizestrant plus continuation of a CDK4/6 inhibitor received accelerated approval for patients whose ESR1 mutation emerges during first-line aromatase inhibitor plus CDK4/6 inhibitor therapy before radiographic progression, under the specific conditions of that indication.
Treatment selection is still broader than one gene. Clinicians consider previous CDK4/6 inhibitor exposure, disease tempo, symptoms, organ involvement, HER2 status, germline findings, and other actionable tumor alterations. An ESR1 result may therefore compete with or complement other options rather than dictate a single treatment.
For example, a patient can have both an ESR1 mutation and another actionable pathway alteration. The oncology team may need to decide which mechanism is most clinically important at that point in the disease course. This is one reason molecular results should be interpreted in context rather than ranked automatically by whether they are labeled “positive.”
Recurrence Monitoring and Test Limitations
ESR1 mutations are associated with treatment resistance and can appear as breast cancer evolves, but an ESR1 test is not a stand-alone recurrence test.
In metastatic disease, serial ctDNA can reveal changing tumor biology. A rising ESR1-mutant clone may indicate that an aromatase-inhibitor-based regimen is selecting for resistant cells. The SERENA-6 strategy demonstrated that molecular progression can sometimes precede radiographic progression and can be used to trigger a treatment change in a carefully defined population.
That concept should not be generalized to every situation. Important limitations include:
- False-negative plasma results: low ctDNA shedding can hide an existing mutation.
- Tumor heterogeneity: one tissue biopsy may miss a mutation present elsewhere.
- Assay differences: panels vary in the ESR1 regions covered and the lowest VAF they can detect.
- Clonal evolution: a result can become outdated after additional treatment.
- Non-ESR1 resistance: progression can occur through many mechanisms even when ESR1 is wild type.
- Uncertain variants: not every ESR1 sequence change has proven clinical significance.
ESR1 status also should not replace routine assessment of receptor phenotype. Metastatic breast cancer can change ER, progesterone receptor, or HER2 expression over time. When clinically feasible, reassessing these features may matter because a HER2/ERBB2 mutation result and a standard HER2 protein/amplification result answer different questions and can lead to different treatment pathways.
For someone previously treated for early-stage breast cancer who develops new symptoms, the priority is clinical evaluation rather than ordering an ESR1 test in isolation. Persistent bone pain, unexplained weight loss, neurologic symptoms, shortness of breath, jaundice, or other concerning changes deserve medical assessment based on their severity and context.
Questions to Ask After ESR1 Testing
A molecular report is most useful when it leads to a specific decision. After receiving an ESR1 result, useful questions include:
- Was the test performed on plasma ctDNA or tumor tissue?
- Which ESR1 mutation was detected, and is it a validated activating mutation?
- Was there enough tumor DNA in the sample for a dependable negative result?
- Does this result explain resistance to my current or previous endocrine treatment?
- Does the result make me eligible for an approved ESR1-directed treatment in my current disease setting?
- Are there other actionable mutations on the same molecular report that also affect treatment choices?
- If the blood test is negative, would testing a recent tumor biopsy add useful information?
- Is repeat ctDNA testing being used as part of a validated treatment strategy, or only for general monitoring?
- How will imaging, symptoms, tumor markers, and the ESR1 result be considered together?
The most important takeaway is that ESR1 is a dynamic resistance biomarker, not a fixed label attached to the original breast cancer diagnosis. The result is most informative when it is recent, technically reliable, and obtained at a point when it can change management.
References
- Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update 2023 (Guideline)
- First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 2025 (RCT)
- FDA grants accelerated approval to camizestrant with a CDK4/6 inhibitor for ESR1-Mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer 2026
- FDA approves imlunestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer 2025
- FDA approves vepdegestrant for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer 2026
- Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial 2022 (RCT)
Disclaimer
ESR1 testing is used mainly to guide treatment decisions in selected patients with advanced or metastatic breast cancer and should be interpreted by an oncology team together with receptor status, prior therapy, imaging, and other molecular findings. A positive ESR1 result does not by itself prove recurrence, and a negative plasma result does not completely exclude an ESR1-mutant tumor. Treatment indications and companion-diagnostic requirements can change as new evidence and regulatory decisions emerge.
